Thus, the combination of EphA2 and HDAC inhibition in endometrial cancer likely causes DNA damage, increased apoptosis, decreased clonogenic survival, and downregulation of the Axl-PI3K-AKT-mTOR pathway. Here, EPHA2 is linked to endometrial cancer.